Age: 64.0
Sex: M
Vaccine: COVID19, UNK
Symptoms: Psoriasis, Therapeutic product effect decreased
Clinical narrative: Psoriasis aggravated; Drug effect decreased; This spontaneous case was reported by a consumer and describes the occurrence of PSORIASIS (Psoriasis aggravated) and THERAPEUTIC PRODUCT EFFECT DECREASED (Drug effect decreased) in a 64-year-old male patient who received mRNA-1273 (Spikevax) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Plaque psoriasis.    No Medical History information was reported.   On an unknown date, the patient received first dose of mRNA-1273 (Spikevax) (Intramuscular) 1 dosage form and ADALIMUMAB (HUMIRA) (Subcutaneous) at an unspecified dose. On an unknown date, the patient experienced PSORIASIS (Psoriasis aggravated) and THERAPEUTIC PRODUCT EFFECT DECREASED (Drug effect decreased). The patient was treated with RISANKIZUMAB (SKYRIZI [RISANKIZUMAB]) at an unspecified dose and frequency. At the time of the report, PSORIASIS (Psoriasis aggravated) and THERAPEUTIC PRODUCT EFFECT DECREASED (Drug effect decreased) outcome was unknown.        The action taken with mRNA-1273 (Spikevax) (Intramuscular) was unknown.       No concomitant medication were reported.  It was reported that patient was not enrolled in covid-19 vaccine trail. Company comment This spontaneous case reported by a consumer, concerns a 64 year old male patient, with no medical history reported, who experienced the unexpected, non serious events of psoriasis (psoriasis aggravated) and therapeutic product effect decreased (drug effect decreased) on an unknown date after receiving  the 1 dose of mRNA 1273 vaccine. patient also received Adalimumab (humira). it was reported that on an unknown date the patient experienced plaque psoriasis break out and took covid vaccine which affected the effectiveness of Humira. Details of clinical course, risk factors, co morbidities, labs, diagnostic investigations and treatment details were not provided. Patient was treated with Risankizumab. Event outcome was unknown. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report. Event seriousness assessed as per medical judgement.   On unknown dates, the patient experienced plaque psoriasis break out and took covid vaccine which affected the effectiveness of Humira.; Sender's Comments: This spontaneous case reported by a consumer, concerns a 64 year old male patient, with no medical history reported, who experienced the unexpected, non serious events of psoriasis (psoriasis aggravated) and therapeutic product effect decreased (drug effect decreased) on an unknown date after receiving  the 1 dose of mRNA 1273 vaccine. patient also received Adalimumab (humira). it was reported that on an unknown date the patient experienced plaque psoriasis break out and took covid vaccine which affected the effectiveness of Humira. Details of clinical course, risk factors, co morbidities, labs, diagnostic investigations and treatment details were not provided. Patient was treated with Risankizumab. Event outcome was unknown. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report. Event seriousness assessed as per medical judgement.